Following the successful completion of a US$45m fund raising ApaTech, a world leader in bone graft technology, announces a major new facility development.

ApaTech has signed leases with ING Real Estate Investment Management acting on behalf of the Skandia Property Fund for a 11.5 year lease on two buildings at Centennial Park, Elstree, for a total of 32,000 square feet of office, manufacturing and development activities. Adjacent to the Company’s current location the new buildings provide a four fold increase in manufacturing capacity, equivalent to sales of US$100-125m and office accommodation for an additional 45 UK based staff.

Planning permission has been received for the $13m development and preparatory work to fit out the new facility has been initiated. Office occupancy is planned for January 2009, with manufacturing for sale intended from August 2009.

Commenting on this announcement CEO Simon Cartmell said “The Elstree site is an excellent location for ApaTech and we are all looking forward to moving into the new facility which will be a world class manufacturing and corporate headquarters, reflecting the Company’s values and ambitions”.

Alistair Fisher of ING stated “ApaTech are an ideal tenant. We have worked with them in building 370 and their rapid growth provides confidence that they continue to be a key part of the community at Centennial Park. We are delighted that the excellent infrastructure in Elstree continues to attract high quality companies”

Ends

Further Information:

ApaTech 
Simon Cartmell, CEO                      +44 (0)20 8731 4640
simon.cartmell@apatech.com       www.apatech.com             

ING Real Estate Investment Management
Helen Stott               +44 (0)20 7767 5648
Helen.stott@ingrealestate.co.uk

Notes to Editors:

About ApaTech

ApaTech Limited, based in London, England, Foxborough, Mass. is a world leader in bone graft technologies. Founded in 2001 and based on research and intellectual property from Queen Mary University of London and Cambridge University, ApaTech has introduced a novel silicate substituted calcium phosphate bone graft material, Actifuse, globally. The company believes that Actifuse is the first of a new class of synthetic bone graft materials that combine osteoconductive and osteo-stimulatory activities and demonstrates the Company’s leadership in applying the science of silicon to bone graft technologies.

The Company raised $23m of venture capital from 3i plc and MTI and $7m of debt from Noble Venture Finance in 2001-7 and a growth equity round of $45m in May and June 2008. ApaTech commercializes its products, Actifuse and ApaPore in 21 countries around the world and is achieving rapid sales growth, with sales of $15.5m in 2007.

ApaTech has locations in Elstree, UK, Berlin, Germany and Foxborough, MA, USA.  The Company sells its products in the US, UK, Germany and 18 other countries around the world. ApaTech was recently recognized as Britain’s fastest growing medical technology company in the 2007 Sunday Times Fast Track 100 fastest growing private companies review.